In prostate cancer, it increases Treg expression, promotes proliferation of myeloid-derived inhibitory cells (MDSCs), angiogenesis, and tumor progression and inhibits CD4+ and CD8+ T lymphocyte levels (16). This evidence concerns the gene CD4 and neoplasm.